Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

A Retrospective Surveillance of the Antibiotics Prophylactic Use of Surgical Procedures in Private Hospitals in Indonesia.

Herawati F, Yulia R, Hak E, Hartono AH, Michiels T, Woerdenbag HJ, Avanti C.

Hosp Pharm. 2019 Oct;54(5):323-329. doi: 10.1177/0018578718792804. Epub 2018 Aug 21.

PMID:
31555008
2.

Antifungal and biofilm inhibitory effect of Cymbopogon citratus (lemongrass) essential oil on biofilm forming by Candida tropicalis isolates; an in vitro study.

Sahal G, Woerdenbag HJ, Hinrichs WLJ, Visser A, Tepper PG, Quax WJ, van der Mei HC, Bilkay IS.

J Ethnopharmacol. 2020 Jan 10;246:112188. doi: 10.1016/j.jep.2019.112188. Epub 2019 Aug 27.

PMID:
31470085
3.

Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly.

Beugeling M, De Zee J, Woerdenbag HJ, Frijlink HW, Wilschut JC, Hinrichs WLJ.

Expert Rev Vaccines. 2019 Sep;18(9):935-950. doi: 10.1080/14760584.2019.1657013. Epub 2019 Aug 25.

PMID:
31446807
4.

A gastrointestinal simulation system for dissolution of oral solid dosage forms before and after Roux-en-Y gastric bypass.

Yska JP, Punter RJ, Woerdenbag HJ, Emous M, Frijlink HW, Wilffert B, van Roon EN.

Eur J Hosp Pharm. 2019 May;26(3):152-156. doi: 10.1136/ejhpharm-2017-001360. Epub 2018 Feb 8.

PMID:
31428323
5.

Oromucosal films: from patient centricity to production by printing techniques.

Tian Y, Orlu M, Woerdenbag HJ, Scarpa M, Kiefer O, Kottke D, Sjöholm E, Öblom H, Sandler N, Hinrichs WLJ, Frijlink HW, Breitkreutz J, Visser JC.

Expert Opin Drug Deliv. 2019 Sep;16(9):981-993. doi: 10.1080/17425247.2019.1652595. Epub 2019 Aug 8.

PMID:
31382842
6.

Identifying critical process steps to protein stability during spray drying using a vibrating mesh or a two-fluid nozzle.

Grasmeijer N, Tiraboschi V, Woerdenbag HJ, Frijlink HW, Hinrichs WLJ.

Eur J Pharm Sci. 2019 Feb 1;128:152-157. doi: 10.1016/j.ejps.2018.11.027. Epub 2018 Dec 3.

7.

Orodispersible films based on blends of trehalose and pullulan for protein delivery.

Tian Y, Visser JC, Klever JS, Woerdenbag HJ, Frijlink HW, Hinrichs WLJ.

Eur J Pharm Biopharm. 2018 Dec;133:104-111. doi: 10.1016/j.ejpb.2018.09.016. Epub 2018 Sep 29.

8.

Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations.

Visser JC, Ten Seldam IEJ, van der Linden IJ, Hinrichs WLJ, Veenendaal RFH, Dijkers ECF, Woerdenbag HJ.

Int J Pharm Compd. 2018 May-Jun;22(3):247-251.

PMID:
29878892
9.

Addition of Pullulan to Trehalose Glasses Improves the Stability of β-Galactosidase at High Moisture Conditions.

Teekamp N, Tian Y, Visser JC, Olinga P, Frijlink HW, Woerdenbag HJ, Hinrichs WLJ.

Carbohydr Polym. 2017 Nov 15;176:374-380. doi: 10.1016/j.carbpol.2017.08.084. Epub 2017 Aug 24.

10.

Increased drug load and polymer compatibility of bilayered orodispersible films.

Carolina Visser J, Weggemans OAF, Boosman RJ, Loos KU, Frijlink HW, Woerdenbag HJ.

Eur J Pharm Sci. 2017 Sep 30;107:183-190. doi: 10.1016/j.ejps.2017.07.010. Epub 2017 Jul 12.

PMID:
28709911
11.

Ready-to-use parenteral amiodarone: a feasibility study towards a long-term stable product formulation.

Jacobs MS, Luinstra M, Moes JR, Chan TCY, Minovic I, Frijlink HW, Woerdenbag HJ.

Eur J Hosp Pharm. 2017 Mar;24(2):110-114. doi: 10.1136/ejhpharm-2015-000860. Epub 2016 Apr 13.

12.

Personalized Medicine in Pediatrics: The Clinical Potential of Orodispersible Films.

Visser JC, Woerdenbag HJ, Hanff LM, Frijlink HW.

AAPS PharmSciTech. 2017 Feb;18(2):267-272. doi: 10.1208/s12249-016-0515-1. Epub 2016 Apr 4. Review.

PMID:
27044380
13.

Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study.

Maurer JM, Hofman S, Schellekens RC, Tonnis WF, Dubois AO, Woerdenbag HJ, Hinrichs WL, Kosterink JG, Frijlink HW.

Int J Pharm. 2016 May 30;505(1-2):175-86. doi: 10.1016/j.ijpharm.2016.03.027. Epub 2016 Mar 17.

PMID:
26997425
14.

Oromucosal film preparations: points to consider for patient centricity and manufacturing processes.

Krampe R, Visser JC, Frijlink HW, Breitkreutz J, Woerdenbag HJ, Preis M.

Expert Opin Drug Deliv. 2016;13(4):493-506. doi: 10.1517/17425247.2016.1118048. Epub 2015 Dec 8. Review.

PMID:
26559519
15.

Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets.

Maurer JM, Schellekens RC, van Rieke HM, Wanke C, Iordanov V, Stellaard F, Wutzke KD, Dijkstra G, van der Zee M, Woerdenbag HJ, Frijlink HW, Kosterink JG.

PLoS One. 2015 Jul 15;10(7):e0129076. doi: 10.1371/journal.pone.0129076. eCollection 2015.

16.

Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films.

Visser JC, Dohmen WM, Hinrichs WL, Breitkreutz J, Frijlink HW, Woerdenbag HJ.

Int J Pharm. 2015 May 15;485(1-2):70-6. doi: 10.1016/j.ijpharm.2015.03.005. Epub 2015 Mar 5.

PMID:
25746737
17.

Orodispersible films in individualized pharmacotherapy: The development of a formulation for pharmacy preparations.

Visser JC, Woerdenbag HJ, Crediet S, Gerrits E, Lesschen MA, Hinrichs WLJ, Breitkreutz J, Frijlink HW.

Int J Pharm. 2015 Jan 15;478(1):155-163. doi: 10.1016/j.ijpharm.2014.11.013. Epub 2014 Nov 7.

PMID:
25448577
18.

Natural products from resurrection plants: potential for medical applications.

Gechev TS, Hille J, Woerdenbag HJ, Benina M, Mehterov N, Toneva V, Fernie AR, Mueller-Roeber B.

Biotechnol Adv. 2014 Nov 1;32(6):1091-101. doi: 10.1016/j.biotechadv.2014.03.005. Epub 2014 Mar 26. Review.

19.

ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability.

Maurer JM, Schellekens RC, van Rieke HM, Stellaard F, Wutzke KD, Buurman DJ, Dijkstra G, Woerdenbag HJ, Frijlink HW, Kosterink JG.

J Control Release. 2013 Dec 28;172(3):618-24. doi: 10.1016/j.jconrel.2013.09.021. Epub 2013 Oct 2.

PMID:
24096020
20.

Vietnamese traditional medicine from a pharmacist's perspective.

Woerdenbag HJ, Nguyen TM, Vu DV, Tran H, Nguyen DT, Tran TV, De Smet PA, Brouwers JR.

Expert Rev Clin Pharmacol. 2012 Jul;5(4):459-77. doi: 10.1586/ecp.12.34. Review.

PMID:
22943125
21.

In vitro regeneration of wild chervil (Anthriscus sylvestris L.).

Hendrawati O, Hille J, Woerdenbag HJ, Quax WJ, Kayser O.

In Vitro Cell Dev Biol Plant. 2012 Jun;48(3):355-361. Epub 2011 Oct 25.

22.

Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making.

Tu HAT, de Vries R, Woerdenbag HJ, Li SC, Le HH, van Hulst M, Postma MJ.

Value Health Reg Issues. 2012 May;1(1):7-14. doi: 10.1016/j.vhri.2012.03.007. Epub 2012 May 25.

PMID:
29702830
23.

Cost of Illness of Chronic Hepatitis B Infection in Vietnam.

Tu HAT, Woerdenbag HJ, Riewpaiboon A, Kane S, Le DM, Postma MJ, Li SC.

Value Health Reg Issues. 2012 May;1(1):23-28. doi: 10.1016/j.vhri.2012.03.008. Epub 2012 May 25.

PMID:
29702821
24.

A non-invasive, low-cost study design to determine the release profile of colon drug delivery systems: a feasibility study.

Maurer MJ, Schellekens RC, Wutzke KD, Dijkstra G, Woerdenbag HJ, Frijlink HW, Kosterink JG, Stellaard F.

Pharm Res. 2012 Aug;29(8):2070-8. doi: 10.1007/s11095-012-0735-3. Epub 2012 Mar 16.

PMID:
22422322
25.

A review of the literature on the economics of vaccination against TB.

Tu HA, Vu HD, Rozenbaum MH, Woerdenbag HJ, Postma MJ.

Expert Rev Vaccines. 2012 Mar;11(3):303-17. doi: 10.1586/erv.11.197. Review.

PMID:
22380823
26.

Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.

Tu HA, Rozenbaum MH, Coyte PC, Li SC, Woerdenbag HJ, Postma MJ.

Vaccine. 2012 Feb 14;30(8):1521-8. doi: 10.1016/j.vaccine.2011.11.052. Epub 2011 Nov 23.

PMID:
22119590
27.

Identification of lignans and related compounds in Anthriscus sylvestris by LC-ESI-MS/MS and LC-SPE-NMR.

Hendrawati O, Woerdenbag HJ, Michiels PJ, Aantjes HG, van Dam A, Kayser O.

Phytochemistry. 2011 Dec;72(17):2172-9. doi: 10.1016/j.phytochem.2011.08.009. Epub 2011 Aug 31.

PMID:
21889175
28.

Economic evaluations of rotavirus immunization for developing countries: a review of the literature.

Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ.

Expert Rev Vaccines. 2011 Jul;10(7):1037-51. doi: 10.1586/erv.11.65. Review.

PMID:
21806398
29.

Applications of stable isotopes in clinical pharmacology.

Schellekens RC, Stellaard F, Woerdenbag HJ, Frijlink HW, Kosterink JG.

Br J Clin Pharmacol. 2011 Dec;72(6):879-97. doi: 10.1111/j.1365-2125.2011.04071.x. Review. Erratum in: Br J Clin Pharmacol. 2013 Apr;75(4):1171.

30.

Seasonal variations in the deoxypodophyllotoxin content and yield of Anthriscus sylvestris L. (Hoffm.) grown in the field and under controlled conditions.

Hendrawati O, Woerdenbag HJ, Hille J, Quax WJ, Kayser O.

J Agric Food Chem. 2011 Aug 10;59(15):8132-9. doi: 10.1021/jf200177q. Epub 2011 Jul 18.

PMID:
21604818
31.

Film coated tablets (ColoPulse technology) for targeted delivery in the lower intestinal tract: influence of the core composition on release characteristics.

Schellekens RC, Baltink JH, Woesthuis EM, Stellaard F, Kosterink JG, Woerdenbag HJ, Frijlink HW.

Pharm Dev Technol. 2012 Jan-Feb;17(1):40-7. doi: 10.3109/10837450.2010.513986. Epub 2010 Oct 5.

PMID:
20923321
32.

Oral ileocolonic drug delivery by the colopulse-system: a bioavailability study in healthy volunteers.

Schellekens RC, Stellaard F, Olsder GG, Woerdenbag HJ, Frijlink HW, Kosterink JG.

J Control Release. 2010 Sep 15;146(3):334-40. doi: 10.1016/j.jconrel.2010.05.028. Epub 2010 May 31.

PMID:
20621586
33.

Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.

Tu HA, Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LT, Postma MJ.

Clin Ther. 2010 Jan;32(1):133-44. doi: 10.1016/j.clinthera.2010.01.015.

PMID:
20171419
34.

Taxomyces andreanae: a presumed paclitaxel producer demystified?

Staniek A, Woerdenbag HJ, Kayser O.

Planta Med. 2009 Dec;75(15):1561-6. doi: 10.1055/s-0029-1186181.

PMID:
19809969
35.

Proof-of-concept study on the suitability of 13C-urea as a marker substance for assessment of in vivo behaviour of oral colon-targeted dosage forms.

Schellekens RC, Olsder GG, Langenberg SM, Boer T, Woerdenbag HJ, Frijlink HW, Kosterink JG, Stellaard F.

Br J Pharmacol. 2009 Sep;158(2):532-40. doi: 10.1111/j.1476-5381.2009.00302.x.

36.

Economic evaluations of hepatitis B vaccination for developing countries.

Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ.

Expert Rev Vaccines. 2009 Jul;8(7):907-20. doi: 10.1586/erv.09.53. Review.

PMID:
19538116
37.

Metabolic stereoselectivity of cytochrome P450 3A4 towards deoxypodophyllotoxin: In silico predictions and experimental validation.

Julsing MK, Vasilev NP, Schneidman-Duhovny D, Muntendam R, Woerdenbag HJ, Quax WJ, Wolfson HJ, Ionkova I, Kayser O.

Eur J Med Chem. 2008 Jun;43(6):1171-9. Epub 2007 Sep 19.

PMID:
17998150
38.

Functional analysis of genes involved in the biosynthesis of isoprene in Bacillus subtilis.

Julsing MK, Rijpkema M, Woerdenbag HJ, Quax WJ, Kayser O.

Appl Microbiol Biotechnol. 2007 Jul;75(6):1377-84. Epub 2007 Apr 26.

39.

HPLC-photodiode array detection analysis of curcuminoids in Curcuma species indigenous to Indonesia.

Bos R, Windono T, Woerdenbag HJ, Boersma YL, Koulman A, Kayser O.

Phytochem Anal. 2007 Mar-Apr;18(2):118-22.

PMID:
17439012
40.

Combinatorial biosynthesis of medicinal plant secondary metabolites.

Julsing MK, Koulman A, Woerdenbag HJ, Quax WJ, Kayser O.

Biomol Eng. 2006 Dec;23(6):265-79. Epub 2006 Aug 22. Review.

PMID:
17049920
41.

Bioconversion of deoxypodophyllotoxin into epipodophyllotoxin in E. coli using human cytochrome P450 3A4.

Vasilev NP, Julsing MK, Koulman A, Clarkson C, Woerdenbag HJ, Ionkova I, Bos R, Jaroszewski JW, Kayser O, Quax WJ.

J Biotechnol. 2006 Nov 10;126(3):383-93. Epub 2006 Jun 5.

PMID:
16753237
42.

Lignans from cell suspension cultures of Phyllanthus niruri, an Indonesian medicinal plant.

Elfahmi, Batterman S, Koulman A, Hackl T, Bos R, Kayser O, Woerdenbag HJ, Quax WJ.

J Nat Prod. 2006 Jan;69(1):55-8.

PMID:
16441068
43.

A phytochemical study of lignans in whole plants and cell suspension cultures of Anthriscus sylvestris.

Koulman A, Kubbinga ME, Batterman S, Woerdenbag HJ, Pras N, Woolley JG, Quax WJ.

Planta Med. 2003 Aug;69(8):733-8.

PMID:
14531024
44.

Determination of valepotriates.

Bos R, Woerdenbag HJ, Pras N.

J Chromatogr A. 2002 Aug 16;967(1):131-46. Review.

PMID:
12219926
45.

Volatile components from Anthriscus sylvestris (L.) Hoffm.

Bos R, Koulman A, Woerdenbag HJ, Quax WJ, Pras N.

J Chromatogr A. 2002 Aug 9;966(1-2):233-8.

PMID:
12214699
46.

Isolation and identification of dihydroartemisinic acid from artemisia annua and its possible role in the biosynthesis of artemisinin

Wallaart TE, van Uden W, Lubberink HG, Woerdenbag HJ, Pras N, Quax WJ.

J Nat Prod. 1999 Mar;62(3):430-3.

PMID:
10096851
47.

Cytotoxicity of natural ginseng glycosides and semisynthetic analogues.

Atopkina LN, Malinovskaya GV, Elyakov GB, Uvarova NI, Woerdenbag HJ, Koulman A, Pras N, Potier P.

Planta Med. 1999 Feb;65(1):30-4.

PMID:
10083841
48.

Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells.

Beekman AC, Wierenga PK, Woerdenbag HJ, Van Uden W, Pras N, Konings AW, el-Feraly FS, Galal AM, Wikström HV.

Planta Med. 1998 Oct;64(7):615-9.

PMID:
9810267
49.

Cytotoxic potential of valerian constituents and valerian tinctures.

Bos R, Hendriks H, Scheffer JJ, Woerdenbag HJ.

Phytomedicine. 1998 May;5(3):219-25. doi: 10.1016/S0944-7113(98)80032-9.

PMID:
23195845

Supplemental Content

Loading ...
Support Center